Journal articles: 'Grand Odile'

1

Sturm, Jessica L., and Randi L. Polk. "Pratique Conjugaison par Odile Grand-Clément and Aline Volte." French Review 96, no. 4 (May 2023): 178. http://dx.doi.org/10.1353/tfr.2023.0095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ribeiro, Rosária Cristina Costa, Odile Pedro Leal, and Karina de Oliveira Barboza. "O teatro guianense contemporâneo: entrevista com Odile Pedro Leal." Cadernos de Literatura em Tradução, no. 25 (December 22, 2022): 280–86. http://dx.doi.org/10.11606/issn.2359-5388.i25p280-286.

Full text

Abstract:

Atriz formada pelo Conservatório Nacional Superior de Bordeaux, diretora de teatro, dramaturga e diretora artística do Grand Théâtre Itinérant de Guyane (Grand T.I.G), sucessor, desde 2017, do Guyane Art Théâtre, Odile Pedro Leal também foi responsável pela missão cultural no Conselho Regional da Guiana entre 2010 e 2012. Podemos dizer que Pedro Leal é uma mulher plural, como a Guiana, como o teatro guianense. Em sua tese de doutorado, Pedro Leal desenvolve o conceito de teatro caché-montré, um teatro presente no cotidiano guianense, especialmente centrado em torno do carnaval: “O carnaval é um teatro escondido, pois dispensa o estrado ou o palco, assim como o profissionalismo do ator para sua realização, e é um teatro mostrado, pois é visivelmente encenado.” (PEDRO LEAL, 2000, p. 37).

APA, Harvard, Vancouver, ISO, and other styles

3

Leal, Odile Pedro, and Rosária Cristina Costa Ribeiro. "Le théâtre Guyanais contemporain: entretien avec Odile Pedro Leal." Cadernos de Literatura em Tradução, no. 25 (December 22, 2022): 273–79. http://dx.doi.org/10.11606/issn.2359-5388.i25p273-279.

Full text

Abstract:

Comédienne, formée au Conservatoire National Supérieur de Bordeaux, metteure en scène, auteure dramatique et directrice artistique du Grand Théâtre Itinérant de Guyane (Grand T.I.G), qui succède depuis 2017 au Guyane Art Théâtre, aussi Chargée de mission culturelle dans le Conseil Régional de Guyane entre 2010 et 2012, nous pouvons dire que Odile Pedro Leal est une femme multiple, comme la Guyane, comme le théâtre guyanais. Dans sa thèse de doctorat, Mme Pedro Leal développe le concept du théâtre caché-montré, un théâtre présent au quotidien guyanais, surtout concentré autour du Carnaval: «Le carnaval est un théâtre caché, parce qu’il se passe du tréteau ou de la scène, comme du professionnalisme de l’acteur, pour sa réalisation; et il est un théâtre montré, parce que visiblement on y joue.» (PEDRO LEAL, 2000, p. 37).

APA, Harvard, Vancouver, ISO, and other styles

4

Jansma, Kimberly. "Conjugaison progressive du français: A2B1 Intermédiaire by Michèle Boularès et Odile Grand-Clément." French Review 96, no. 1 (October 2022): 270. http://dx.doi.org/10.1353/tfr.2022.0153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Klein, Laurent. "Daniel Sibony, Le Grand Malentendu , Islam, Israël, Occident. Odile Jacob, 2015, 182 pages, 19,90 €." Études juillet-août, no. 7 (June 23, 2015): XX. http://dx.doi.org/10.3917/etu.4218.0123t.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dolbeault, Joël. "Thomas Séon, Les lois d’échelle, La physique du petit et du grand . Odile Jacob, « Sciences », 2018, 256 pages, 22,90 €." Études Juin, no. 6 (May 20, 2019): XVIII. http://dx.doi.org/10.3917/etu.4261.0117r.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gounin, Yves. "Le Grand Basculement. La question sociale à l’échelle mondiale / Jean-Michel Severino, Olivier Ray. Paris, Odile Jacob, 2011, 299 p." Revue internationale et stratégique 86, no. 2 (May 1, 2012): XXVI. http://dx.doi.org/10.3917/ris.086.0123z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lieu, Judith M. "Marie-Odile Goulet-Cazé, Cynicism and Christianity in Late Antiquity (Grand Rapids, MI: William B. Eerdmans, 2019), pp. xvii + 278. $75.00." Scottish Journal of Theology 73, no. 4 (November 2020): 367–69. http://dx.doi.org/10.1017/s0036930620000150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Torchin, Danielle. "HENRI DANON-BOILEAU, GéRARD DEDIEU-ANGLADE, Une certaine forme d’obstination. Vivre le très grand âge, Editions Odile Jacob, 2014, 297 pages, 23,90€." Le Carnet PSY N° 184, no. 8 (October 24, 2014): III. http://dx.doi.org/10.3917/lcp.184.0013c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Perrot, Étienne. "Tommaso Padoa-Schioppa & Beda Romano , Contre la courte vue , Entretiens sur le Grand Krach . Odile Jacob, 2009, 202 pages, 21 €." Études Tome 412, no. 3 (March 1, 2010): XXIX. http://dx.doi.org/10.3917/etu.4123.0405ac.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Renouard, Cécile. "Jean-Michel Sévérino & Olivier Ray . Le grand basculement . La question sociale à l’échelle mondiale . Odile Jacob, 2011, 299 pages, 25,90 €." Études Tome 416, no. 1 (January 1, 2012): XXVI. http://dx.doi.org/10.3917/etu.4161.0119z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lambauer, Barbara. "Pollack Martin , Empereur d’Amérique : le grand exode de Galicie , trad. de l’allemand par Odile Demange, Lausanne, Éd. Noir sur Blanc, 2015, 256 p., 21 €." Vingtième Siècle. Revue d'histoire N° 133, no. 1 (December 19, 2016): V. http://dx.doi.org/10.3917/ving.133.0185e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Evrard, Albert. "Henri Danon-Boileau & Gérard Dedieu-Anglade . Une certaine forme d’obstination . Vivre le très grand âge. Odile Jacob, 2012, 303 pages, 24,20 €. Dominique Raoul-Duval . Mère Amour . Chronique du grand âge. Nil Éditions, 2012, 203 pages, 18,25 €." Études Tome 417, no. 11 (November 1, 2012): XXXV. http://dx.doi.org/10.3917/etu.4175.0549ai.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Loiseau, Hugo. "Luttwak, Edward N., Le grand livre de la stratégie, de la paix et de la guerre, Paris, Odile Jacob, 2 éd. (1 éd. 1987), 2002, 400 p." Études internationales 34, no. 4 (2003): 663. http://dx.doi.org/10.7202/038695ar.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Euvé, François. "Le mythe de l’architecte cosmique , Stephen Hawking et Leonard Mlodinow, Y a-t-il un grand architecte dans l’Univers ?, Trad. de l’anglais (États-Unis) par M. Filoche, Odile Jacob, 2011, 240 pages, 22,90 €." Études Tome 415, no. 9 (August 30, 2011): II. http://dx.doi.org/10.3917/etu.4153.0255b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Lucas, Amand A. "Compte rendu de Sébastien Balibar : «Savant cherche refuge : comment les grands noms de la science ont survécu à la Seconde guerre mondiale»." Revue des questions scientifiques 190, no. 3-4 (December 1, 2019): 460–62. http://dx.doi.org/10.14428/qs.v190i3-4.70613.

Full text

Abstract:

Balibar (Sébastien), Savant cherche refuge : comment les grands noms de la science ont survécu à la Seconde Guerre mondiale. – Paris : Odile Jacob, 2019. – 252 p. – 1 vol. broché de 14,5 × 22 cm. – 23,90 €. – isbn 978-2-7381-4657-1.

APA, Harvard, Vancouver, ISO, and other styles

17

Carvalho, Joseane de, and Fernando Frachone Neves. "ADOÇÃO DE PRÁTICAS SUSTENTÁVEIS COMO DIFERENCIAL COMPETITIVO: ESTUDO DE CASO DE UMA INDÚSTRIA DE CACHAÇA." Revista Acadêmica Online 10, no. 51 (May 9, 2024): 1–12. http://dx.doi.org/10.36238/2359-5787.2024.v10n51.114.

Full text

Abstract:

A cachaça é uma bebida muito popular e é genuinamente brasileira, sendo a terceira bebida destilada mais consumida no mundo, movimentando grande quantidade de recursos financeiros. Segundo o Ministério da Agricultura e Pecuária, em 2021, 936 produtores formalizados foram responsáveis por 4,969 rótulos do produto. Em expansão no Brasil, a indústria busca inovar não somente em métodos e implementação de tecnologias, como também agregar valor aos produtos fabricados, levando-se em consideração a inserção de padrões de qualidade ambiental. No presente estudo, objetivou-se analisar algumas estratégias ambientais, no processo de fabricação de cachaças da Cachaça Dona Odila, uma indústria localizada em Jaboticabal, Estado de São Paulo. Para tanto, o presente estudo caracterizou-se como exploratório, com abordagem qualitativa, havendo-se utilizado o procedimento técnico de estudo de caso. Os resultados demonstraram que a Cachaça Dona Odila prima por agregar valor ao produto, mantendo uma cultura conservacionista dos recursos naturais, alinhadas aos objetivos globais para 2030, ou seja, os Objetivos de Desenvolvimento Sustentável (ODS), em sua linha de produção. Conclui-se que a adoção de práticas sustentáveis observadas, podem tornar os produtos mais atrativos a um público mais seletivo e instruído, sendo um importante diferencial competitivo deste mercado.

APA, Harvard, Vancouver, ISO, and other styles

18

Ouanassa Siari Tengour. "Une historienne au cœur de l’Afrique." Africa Review of Books 4, no. 1 (June 20, 2008): 14. http://dx.doi.org/10.57054/arb.v4i1.4738.

Full text

Abstract:

« Mama Africa », hommage à Catherine Coquery-Vidrovitch de Chantal Chanson-Jabeur et Odile Goerg.Paris, L’Harmattan, 2006, 477 pages. Comme son titre le souligne, les contributions de ce bel ouvrage sont of fertes à Catherine Coquery-Vidrovitch, spécialiste de l’histoire contemporaine de l’Afrique. Catherine Coquery-Vidrovitch s’inscrit dans la lignée des grands maîtres de l’histoire de l’Afrique : Henri Brunschwig, Charles André Julien, Charles Robert Ageron, Jean Suret Canale, Joseph Ki Zerbo. Chantal Chanson Jabeur a conçu un abécédaire qui retrace l’itinéraire de Catherine Coquery-Vidrovitch, depuis la création et l’animation du groupe de recherches « Connaissance du Tiers-Monde », ancêtre de l’actuel laboratoire SEDET (Sociétés en développement dans l’espace et dans le temps), rattaché au CNRS. Mais ce n’est pas la seule tâche à laquelle Catherine Coquery-Vidrovitch a voué son temps : outre les enseignements d’histoire, elle a fait soutenir plus d’une centaine de thèses où la colonisation/décolonisation de l’Afrique demeure le thème central, recoupé sans cesse par l’exploration de nouveaux objets tels le champ de l’histoire économique et politique, les villes et le processus d’urbanisation, la transmission des savoirs, les femmes…

APA, Harvard, Vancouver, ISO, and other styles

19

Becker, Jean-Jacques. "Nicolas Offenstadt, Les fusillés de la Grande Guerre et la mémoire collective (1914-1999), Paris, Éditions Odile Jacob, 1999, 285 p." Annales. Histoire, Sciences Sociales 56, no. 1 (February 2001): 265–67. http://dx.doi.org/10.1017/s0395264900000536.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bonnaure, Pierre. "PICQ Pascal, Qui va prendre le pouvoir ? Les grands singes, les hommes politiques ou les robots , Paris : Odile Jacob, mai 2017, 336 p." Futuribles N° 421, no. 6 (November 2, 2017): I. http://dx.doi.org/10.3917/futur.421.0111a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Gyssels, Kathleen, and Odile Hamot. "Ti Jean L’Horizon à l’âge des mangas. Entretien avec Roland Monpierre." RELIEF - Revue électronique de littérature française 15, no. 2 (December 27, 2021): 117–26. http://dx.doi.org/10.51777/relief11443.

Full text

Abstract:

Roland Monpierre est un artiste guadeloupéen aux multiples casquettes : auteur de bandes dessinées, il est également illustrateur et scénariste. À l’occasion de la publication prochaine de son adaptation en bande dessinée de Ti Jean L’Horizon, le second roman de Simone Schwarz-Bart, il s’est entretenu avec Kathleen Gyssels et Odile Hamot sur les circonstances, les conditions et les enjeux de sa démarche artistique. Que les romans schwarz-bartiens se prêtent à l’adaptation est indéniable : La Mulâtresse Solitude a déjà fait l’objet d'une version en bande dessinée, réalisée par l’Unesco en 2015 dans une série consacrée aux grandes figures de l’Afrique ; Le Dernier des Justes a failli se voir réédité dans une version allégée, illustrée par des dessins de Marc Chagall, et ce n’est que justice que Ti Jean trouve en la personne de Roland Monpierre, un artiste susceptible de magnifier, dans un autre genre et avec d’autres moyens, le caractère éminemment visuel de l’écriture de Simone. Après plusieurs albums tirés des meilleurs auteurs antillais, parmi lesquels Joseph Zobel, ou mettant en lumière des figures oubliées du patrimoine culturel guadeloupéen, telles que le Chevalier de Saint-Georges, ou s’attachant à des grands noms de la culture caribéenne, à l’instar de Bob Marley, Roland Monpierre s’est consacré avec bonheur à cette magnifique odyssée fondée sur le conte antillais et la figure folklorique de Ti Jean. La bande dessinée vient ainsi donner un second souffle au roman de 1979 et toucher un public différent, sans doute bien plus lecteur de mangas que de romans et méconnaissant peut-être même les grandes œuvres de la littérature caribéenne.

APA, Harvard, Vancouver, ISO, and other styles

22

Levin, Myron J., Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Seth Seegobin, Alison Templeton, et al. "LB5. PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S810. http://dx.doi.org/10.1093/ofid/ofab466.1646.

Full text

Abstract:

Abstract Background Vaccines effectively prevent COVID-19, but some individuals have medical comorbidities or receive therapies that impair their immune response to vaccination, or are ineligible for vaccination. For such individuals who remain at risk of COVID-19, monoclonal antibodies may provide additional rapid protection. AZD7442 comprises 2 fully human extended half-life SARS-CoV-2–neutralizing antibodies that bind distinct epitopes of the viral spike protein receptor binding domain. AZD7442 is in development for the prevention and treatment of COVID-19. Here, we report primary Phase 3 study results of AZD7442 for pre-exposure prophylaxis of symptomatic COVID-19. Methods PROVENT (NCT04625725) is a Phase 3, 2:1 randomized, double-blind, placebo-controlled study of a single 300-mg AZD7442 dose (2 intramuscular injections; 150 mg each of tixagevimab and cilgavimab) for symptomatic COVID-19 prevention. Participants were unvaccinated adults (≥ 18 years old) without prior SARS-CoV-2 infection, who may benefit from immunoprophylaxis with antibodies due to an increased risk of either inadequate response to vaccination or SARS-CoV-2 exposure. The primary study endpoints were first case of SARS-CoV-2 RT-PCR-positive symptomatic illness post dose and prior to Day 183 (efficacy), and safety of AZD7442. Results In total, 5197 participants (mean age 53.5 years, 46% female) were randomized and dosed (safety analysis set): AZD7442 n=3460; placebo n=1737. In the primary efficacy analysis (full pre-exposure analysis set, n=5172), AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval 46.0, 90.0) vs placebo (P< 0.001) (Table). Adverse events occurred in 35% and 34% of participants administered AZD7442 and placebo, respectively, and injection site reactions occurred in 2.4% and 2.1% of participants, respectively (safety analysis set). There was 1 case of severe/critical COVID-19 and 2 COVID-19–related deaths in the placebo arm. Conclusion The primary study endpoints were met: a one-time dose of AZD7442 demonstrated statistically significant protection against symptomatic COVID-19 and was well tolerated. AZD7442 is the first long-acting monoclonal antibody combination that represents a potential new option to augment COVID-19 prevention. PROVENT funding statement image Disclosures Myron J. Levin, MD, GSK group of companies (Employee, Research Grant or Support) Andrew Ustianowski, MBBS, Vir/GlaxoSmithKline (Advisor or Review Panel member) Stéphane De Wit, MD, Gilead (Grant/Research Support)Janssen (Grant/Research Support)Merck Sharpe & Dohme (Grant/Research Support)ViiV Healthcare (Grant/Research Support) Odile Launay, MD, PhD, AstraZeneca (Grant/Research Support)GlaxoSmithKline (Consultant, Grant/Research Support, Other Financial or Material Support, Data safety monitoring board)Johnson & Johnson (Consultant, Grant/Research Support)Moderna (Consultant)Pfizer (Consultant, Grant/Research Support)Sanofi Pasteur (Consultant, Grant/Research Support) Miles Avila, MPH, GStat, AstraZeneca (Employee, Shareholder) Seth Seegobin, PhD, AstraZeneca (Employee, Shareholder) Alison Templeton, PhD, AstraZeneca (Employee, Shareholder) Yuan Yuan, PhD, AstraZeneca (Employee, Shareholder) Philip Ambery, FRCP, AstraZeneca (Employee, Shareholder) Rosalinda H. Arends, PhD, AstraZeneca (Employee, Shareholder) Rohini Beavon, PhD, AstraZeneca (Employee, Shareholder) Karen A. Near, MD, AstraZeneca (Employee, Shareholder) Kelly W. Padilla, PharmD, AstraZeneca (Employee, Shareholder) Konstantina Psachoulia, PhD, AstraZeneca (Employee, Shareholder) Audrey Sharbaugh, PhD, AstraZeneca (Employee, Shareholder) Katie Streicher, PhD, AstraZeneca (Employee, Shareholder) Menelas N. Pangalos, PhD, AstraZeneca (Employee, Shareholder) Mark T. Esser, PhD, AstraZeneca (Employee, Shareholder) Robert A. Gasser, Jr., MD, AstraZeneca (Employee, Shareholder)

APA, Harvard, Vancouver, ISO, and other styles

23

Gugelot, Frédéric. "Gaultier-Voituriez Odile , Chronique cachée de la Grande Guerre. Lettre d’Étienne de Nalèche à Pierre Lebaudy (1914-1919) , Paris, CNRS éditions, 2017, 471 p., 27 €." Vingtième Siècle. Revue d'histoire N° 140, no. 4 (October 26, 2018): IV. http://dx.doi.org/10.3917/ving.140.0191d.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

DENCH, GEOFF. "Claudine Attias-Donfut and Martine Segalen, Grands-Parents: la Famille à travers les Générations, Odile Jacob, Paris, 1998, 330 pp., pbk FF135, ISBN 2 7381 0647 1." Ageing and Society 20, no. 3 (May 2000): 377–85. http://dx.doi.org/10.1017/s0144686x9921776x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Housiel, Sylvie. "Roynette Odile, Siouffi Gilles et Steuckardt Agnès (dir.), La langue sous le feu: mots, textes, discours de la Grande Guerre. Rennes: Presses universitaires de Rennes, 2017, 267 pp. 978 2 7535 5312 5 (broché)." Journal of French Language Studies 29, no. 1 (December 11, 2017): 137–38. http://dx.doi.org/10.1017/s0959269517000242.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Larosa, M., N. Morel, M. Belhocine, A. Ruffatti, N. M. Silva, R. Paul, L. Mouthon, et al. "THU0275 SEVERE PREECLAMPSIA RELATED TO ANTIPHOSPHOLIPID SYNDROME: AN EUROPEAN STUDY OF 40 WOMEN." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 364.2–364. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5901.

Full text

Abstract:

Background:One of the 3 features of obstetrical antiphospholipid syndrome (APS) is severe preeclampsia (PE). Its time of occurrence, the associated risk of thromboses and systemic lupus erythematosus (SLE) have not been reported yet.Objectives:We analyzed severe PE in a series of women with APS.Methods:We retrospectively collected data of female patients from 5 French internal medicine and 1 Italian rheumatology units. Inclusion criteria were: a severe PE/eclampsia(1), that occurred before 34 weeks of gestation (WG) in patients who met the APS classification criteria(2).Results:40 patients were enrolled (Table 1). Because of known APS/positive aPL/previous obstetrical complications, 23(57.5%) patients were treated during the index PE: 4 with low dose aspirin (LDA), 4 with low molecular weight heparin (LMWH), and 15 with a combination of both. 7 patients were also treated with hydroxychloroquine, 8 with corticosteroids and 3 with immunosuppressants. 17(42.5%) patients received no treatment. 24(60%) live births were observed. During a follow-up period of 3 years, 26(65%) patients had at least 1 new pregnancy, with a total of 38 pregnancies which resulted in 33(86.8%) live births. 57.5% pregnancies who resulted in live births occurred without any maternal or fetal complications. All 26 patients who had at least 1 pregnancy after index PE were treated with LDA; LMWH was given at prophylactic and therapeutic dosage in 13(50%) patients, respectively. No patient experienced 3 consecutive miscarriages.Table 1.40 APS patients with severe PEOverall features (n, %)Patients40 (100)Age at PE, (median, IQR)30.5 (27-33)PE term, WG (median, IQR)25.5 (23-29) Live births24 (60) Birth term, WG (median, IQR)25.5 (23.7-30.3) Associated SLE12 (30)Maternal complications (n, %)25 (62.5) HELLP18 (45) E6 (15) CAPS3 (7.5) Placental abruptions3 (7.5)Fetal complications (n, %)31 (77.5) IUGR18 (45) IUFD11 (2.5) Preterm delivery22 (55)Obstetrical history (n, %) Primiparous21 (52.5) Index PE before APS12 (30)Thrombosis (n, %) Thrombosis before PE index14 (35.0) Thrombosis after PE index2 (5.0)Abs at APS diagnosis (n, %) aPL triple positivity21 (52.5) IgG/IgM anti-cardiolipin34 (85.0) IgG/IgM anti-β2GPI25 (62.5) LAC33 (82.5)Legend to Table 1:PE: preeclampsia; APS: antiphospholipid syndrome; IQR: interquartile range; WG: weeks of gestation; SLE: systemic lupus erythematosus; HELLP: Hemolysis, elevated liver enzymes, low platelet; E: eclampsia; CAPS: catastrophic APS; IUGR: intrauterine growth restriction; IUFD: intrauterine fetal death; CHB: congenital atrioventricular block; aPL: antiphospholipid antibodies; LAC: lupus anticoagulant.Conclusion:Among the APS criteria, “3 consecutive miscarriages criterion” was not found. The majority of patients also experienced thrombosis and SLE before the index PE.References:[1]Diagnosis and Management of preeclampsia and eclampsia. International Journal of Gynecology &Obestetrics 2002;77:67-75.[2]Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295e 306.Disclosure of Interests:Maddalena Larosa: None declared, Nathalie Morel: None declared, Meriem BELHOCINE: None declared, Amelia Ruffatti: None declared, Nicolas Martin Silva: None declared, Romain Paul: None declared, Luc Mouthon: None declared, Michel DREYFUS: None declared, Jean-Charles PIETTE: None declared, Odile Souchaud-Debouverie: None declared, Catherine Deneux-Tharaux: None declared, Vassilis Tsatsaris: None declared, Emmanuelle Pannier: None declared, Gaêlle Guettrot Imbert: None declared, Véronique LE GUERN Grant/research support from: UCB for GR2 study (to our institution), Andrea Doria Consultant of: GSK, Pfizer, Abbvie, Novartis, Ely Lilly, Speakers bureau: UCB pharma, GSK, Pfizer, Janssen, Abbvie, Novartis, Ely Lilly, BMS, Nathalie Costedoat-Chalumeau Grant/research support from: UCB to my institution

APA, Harvard, Vancouver, ISO, and other styles

27

Sarbu, A. C., S. Guler, O. Stadler, Y. Allanore, V. Bernardino, J. H. W. Distler, A. Gabrielli, et al. "POS0873 PERSISTENT INFLAMMATION IN SYSTEMIC SCLEROSIS IS STRONGLY ASSOCIATED WITH SEVERE DISEASE AND MORTALITY: AN ANALYSIS FROM THE EUSTAR DATABASE." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 731–32. http://dx.doi.org/10.1136/annrheumdis-2022-eular.2123.

Full text

Abstract:

BackgroundSystemic sclerosis (SSc) is a heterogeneous autoimmune disease, with a high disease-related mortality and morbidity. A subset of patients show elevated CRP levels (20-35%), which has been reported as inflammatory SSc. Preliminary data suggest that this subset is characterized by a severe phenotype.ObjectivesTo analyse the phenotype and the survival of inflammatory compared with non-inflammatory SSc patient subsets.MethodsData from 8571 SSc patients with available CRP measurement from the EUSTAR cohort were analysed. Exclusion criteria included acute infection, missing follow-up and tocilizumab treatment. Patients with a CRP ≥5mg/l at ≥80% of visits were stratified as persistent inflammatory and as non-inflammatory if CRP was ≥5 mg/l at <20% of visits (as described previously (1)). As a sensitivity analysis, patients were defined as inflammatory and non-inflammatory based on a single CRP measurement at baseline only (CRP ≥5 or <5mg/l, respectively). We compared baseline characteristics using Chi-square and non-parametric Kruskal–Wallis tests as appropriate. Kaplan Meier curves with log-rank tests were used to estimate time from baseline to death or censoring, and Cox regression to compare mortality risks adjusted for time from diagnosis to baseline.ResultsOut of 2883 patients with more than two visits, 404 (14%) showed persistent inflammation and 1032 (36%) a non-inflammatory phenotype. Out of 5619 patients with more than one visit, 1830 (33%) were stratified as inflammatory as defined by as single CRP measurement at baseline and 3789 (67%) as non-inflammatory. With both definitions, the inflammatory subset revealed a more severe phenotype than non-inflammatory patients, including more frequent diffuse-cutaneous disease, anti-Scl-70 autoantibodies, pulmonary fibrosis, pulmonary hypertension, higher modified Rodnan skin score, and lower forced vital capacity and diffusing capacity for carbon monoxide. Patients with persistent inflammation had a strongly increased risk of all-cause mortality (HR 7.1 [95%CI 3.7 to 13.5], p<0.001) compared to non-inflammatory patients, whereas this association was weaker when based on a single CRP measurement (HR 2.6 [95%CI 2.1 to 3.2], p<0.001).ConclusionThe severe phenotype and decreased survival of the inflammatory SSc subset, which was most prominent in patients with persistently elevated CRP levels, suggest a distinct disease subset. Therefore both, the need for more regular monitoring of inflammatory parameters and implications for immune-modulating treatment, needs to be carefully analysed.References[1]Mitev, A., et al., Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide. Arthritis Res Ther, 2019. 21(1): p. 262. PMID: 31791379Figure 1.Overall mortality from baseline onward a. by persistent inflammatory phenotype, b. by inflammatory phenotype at baselineDisclosure of InterestsAdela-Cristina Sarbu: None declared, Sabina Guler: None declared, Odile Stadler: None declared, Yannick Allanore: None declared, Vera Bernardino: None declared, Jörg H.W. Distler: None declared, Armando Gabrielli: None declared, Anna-Maria Hoffmann-Vold: None declared, Marco Matucci-Cerinic: None declared, Ulf Müller-Ladner: None declared, Vera Ortiz-Santamaria: None declared, Simona Rednic: None declared, Valeria Riccieri: None declared, Vanessa Smith: None declared, Susanne Ullman: None declared, Ulrich Walker: None declared, Thomas Geiser: None declared, Oliver Distler: None declared, Britta Maurer Speakers bureau: Boehringer-Ingelheim, Consultant of: Novartis, Boehringer Ingelheim, Janssen-Cilag, Grant/research support from: AbbVie, Protagen, Novartis Biomedical Research, Florian Kollert Shareholder of: Roche, Consultant of: BMS, Actelion, Boehringer-Ingelheim, Pfizer, Grant/research support from: Roche, Gilead, Pfizer, Employee of: Roche

APA, Harvard, Vancouver, ISO, and other styles

28

Letarouilly, J. G., J. Paccou, S. Badr, R. M. Flipo, C. Chauveau, B. Cortet, O. Broux, and A. Clabaut. "POS0345 ASSESSMENT OF THE EFFECT OF TOFACITINIB ON BONE MARROW ADIPOCYTES AND BONE-FORMING OSTEOBLASTS UNDER NON-INFLAMMATORY AND INFLAMMATORY CONDITIONS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 426.2–426. http://dx.doi.org/10.1136/annrheumdis-2022-eular.802.

Full text

Abstract:

BackgroundSystemic inflammation is the main factor underlying secondary osteoporosis in patients with rheumatoid arthritis (RA). The JAK inhibitors, such as Tofacitinib (Tofa), can control systemic inflammation and have beneficial effects on bone in various models. This might be due to direct effects on the bone microenvironment and not exclusively based on their anti-inflammatory function. Bone marrow adipocytes (BMAds) are abundant in the bone microenvironment. The effect of JAK inhibitors on BMAds is unknown, but evidence suggests that there is competition between human bone marrow-derived stromal cell (hBMSCs) differentiation routes toward BMAds and osteoblasts (Ob) in osteoporosis.ObjectivesTo determine in various models whether Tofa influences directly bone marrow cell committment toward adipogenesis and osteoblastogenesis. Then, in a prospective pilot study, to investigate the potential effects of Tofa on bone marrow adiposity in patients with RA.MethodsTo study the effect of Tofa on cellular commitment, hBMSCs were cultured for 3 days in appropriate Ob- and BMAd- differentiation media (Ob-3d and BMAd-3d), together with Tofa at 200, 400 (equivalent to a therapeutic dose of 5 mg twice a day in RA patients) or 800 nM. To mimic inflammatory conditions, TNFα was added to the media at a dose of 1 ng/ml. This study was also conducted on mature BMAds and a similar treatment was applied for 6 days to mature BMAds at 14 days of differentiation (BMAd-20d). The impact of Tofa was determined by gene expression profile analysis, western-blot analysis and cell density monitoring. In parallel, in a pilot study of 9 RA patients treated with Tofa 5 mg twice a day (TOFAT study: NCT04175886), proton density fat fraction (PDFF) was measured by MRI (Dixon technique) at the lumbar spine at the start of treatment and at 6 months.ResultsIn non-inflammatory conditions, the gene expression of Runx2 decreased in Ob-3d treated with Tofa 400 and 800 nM(p<0.05). Conversely, BMAd-3d treated with Tofa (at 200, 400 and 800 nM) exhibited a substantial increase in the gene expression of PPARγ2, C/EBPα and Perilipin 1 (a marker associated with lipid droplet formation) compared to controls (p<0.05). The increase in the expression of Perilipin 1 was also confirmed at the protein level. In inflammatory conditions, BMAd-3d and Ob-3d markers decreased considerably (PPARy2 and RUNX2, respectively, p<0.05), but the addition of Tofa did not change the expression profiles of Ob-3d compared to TNFα controls. On the contrary, the analysis of PPARy2 gene expression showed that Tofa limited the negative effect of TNFα on BMAd differentiation (p<0.05). The positive effect of Tofa on mature adipocyte (BMAd-20d) under inflammatory conditions was also supported by an increase in the density of differentiated BMAds (p<0.001). These findings were consolidated by an increase in PDFF at 6 months of treatment with Tofa in RA patients (+6.9%, p<0.01).ConclusionOverall, in vitro and clinical results suggest a stimulatory effect of Tofa on BMAds commitment and differentiation, which does not support a positive effect of Tofa on boneDisclosure of InterestsJean-Guillaume Letarouilly Consultant of: Sêmeia, Grant/research support from: Pfizer, Julien Paccou: None declared, Sammy Badr: None declared, René-Marc Flipo Consultant of: member of the advisory board Pfizer, Christophe Chauveau: None declared, Bernard Cortet: None declared, Odile Broux: None declared, Aline Clabaut: None declared

APA, Harvard, Vancouver, ISO, and other styles

29

Ehrenberg, Alain. "Grand résumé de La Mécanique des passions. Cerveau, comportement, société, Paris, Éditions Odile Jacob, 2018." SociologieS, October 27, 2019. http://dx.doi.org/10.4000/sociologies.12381.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

VALLAS, Sophie. "Les Grands Entretiens d’e-Rea, making of : entretien avec Sophie Vallas (par Marie-Odile Pittin-Hédon)." E-rea, no. 21.1 (December 15, 2023). http://dx.doi.org/10.4000/erea.16744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bo, Beatrice Dal, and Chantal Wionet. "Odile Roynette et alii (dir.), La Langue sous le feu. Mots, textes et discours de la Grande Guerre." Cahiers de praxématique, no. 68 (October 16, 2017). http://dx.doi.org/10.4000/praxematique.4621.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Lynch, Édouard. "Nicolas OFFENSTADT, Les fusillés de la grande guerre et la mémoire collective, Paris, Éditions Odile Jacob, 2000, 286 p." Cahiers d’histoire, no. 46-3/4 (December 1, 2001). http://dx.doi.org/10.4000/ch.437.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

"Un nuevo miembro del CICR." Revista Internacional de la Cruz Roja 10, no. 67 (February 1985): 35. http://dx.doi.org/10.1017/s0250569x00004064.

Full text

Abstract:

El Comité International de la Cruz Roja cuenta, desde el 1 de enero de 1985, con un nuevo miembro, el señor Odilo Guntern, nacido en 1937, oriundo de Brig, cantón de Valais.Tras efectuar estudios de derecho en las Universidades de Friburgo, Berna, y Milán, el señor Guntern obtuvo su licenciatura en derecho el año 1961 y su doctorado en 1968. Dirige, desde 1964, su propio bufete de abogado y notario, en Brig.El señor Guntern también hizo carrera en la vida pública. Primeramente, fue miembro del Consejo Municipal de su ciudad natal, Brig, de 1964 a 1975; luego, fue miembro del Grand Conseil (parlamento cantonal) de Valais, de 1969 a 1975.En 1975, fue elegido diputado para representar a su cantón en el Consejo de los Estados (cámara alta del Parlamento Federal suizo) en Berna. Fue presidente de la Comisión para Asuntos Exteriores de ese Consejo y miembro de la Comisión para el Comercio Exterior y las Comunicaciones. Fue miembro del Consejo de los Estados hasta el año 1983.

APA, Harvard, Vancouver, ISO, and other styles

34

Launay, Odile, Marine Cachanado, Liem Binh Luong, Laetitia Ninove, Marie Lachâtre, Inès Ben Ghezala, Marc Bardou, et al. "1954. Immunogenicity against SARS CoV-2 ancestral strain and variants of two new COVID-19 recombinant adjuvanted vaccines compared to BNT162b2 as a third dose following two doses of BNT162b2: a single-blinded multicenter randomized controlled trial." Open Forum Infectious Diseases 9, Supplement_2 (December 1, 2022). http://dx.doi.org/10.1093/ofid/ofac492.1580.

Full text

Abstract:

Abstract Background New adjuvanted recombinant protein vaccines against coronavirus disease 2019 (COVID-19) as heterologous boosters could maximize the benefits of vaccination against SARS CoV-2. Methods In this randomized, single-blinded, multicenter trial, adults who had received two doses of Pfizer-BioNTech mRNA vaccine (BNT162b2) 3–7 months before were randomly assigned to receive a boost of BNT162b2, Sanofi/GSK SARS-CoV-2 adjuvanted recombinant protein MV D614 (monovalent parental formulation) or SARS-CoV-2 adjuvanted recombinant protein MV B.1.351 vaccine (monovalent Beta formulation). The primary endpoint was the percentage of subjects with a ≥ 10-fold increase in neutralizing antibody titers for the Wuhan (D614) and B.1.351 (Beta) SARS-CoV-2 viral strains between D0 and D15. Results The percentages of participants whose neutralizing antibody titers against the Wuhan (D614) SARS-CoV-2 strain increased by a factor ≥ 10 between Day 0 and Day 15 was 55.3% (95% CI 43.4-66.7) in MV(D614) group (n=76), 76.1% (64.5-85.4) in MV(Beta) group (n=71) and 63.2% (51.3-73.9) in BNT162b2 group (n=76). These percentages were 44.7% (33.3-56.6), 84.5% (74.0-92.0) and 51.3% (39.6-63.0) for the B.1.351 (Beta) viral strain, respectively. Higher neutralizing antibodies rates against Delta and Omicron BA.1 variants were also elicited after Sanofi/GSK MV(Beta) vaccine compared to the other vaccines. Comparable reactogenicity profile was observed the three vaccines. Table 1.Characteristics of patients at inclusion (per-protocol population).Figure 2.Neutralizing antibodies against D614 (wild-type; Wuhan) SARS-CoV-2 and variants Beta, Delta and Omicron BA.1 at D0, D15 and D28 after the boost dose (“post D3”)with Sanofi/GSK-D614, Sanofi/GSK-B.1.351 or BNT162b2 (per-protocol population); dotted line represents the positivity threshold.Figure 4.Rates and grades of severity of solicited adverse events reported from D0 to D7 by participants from the three randomized groups of the safety population (G1, Sanofi/GSK-D614; G2, Sanofi/GSK-B.1.351; G3, BNT162b2) according to the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (Modified FDA scale/September 2007) Conclusion All three vaccines boosted antibodies and neutralizing response after BNT162b2 initial course. Heterologous boosting with the Sanofi/GSK SARS-CoV-2 adjuvanted recombinant protein vaccine B.1.351 (Beta formulation) provided higher neutralizing antibodies response rates against variants, including Omicron BA.1, compared with the mRNA BNT162b2 vaccine. Disclosures Odile Launay, MD, PhD, AstraZeneca: Financial|GlaxoSmithKline: Advisor/Consultant|GlaxoSmithKline: Grant/Research Support|Johnson & Johnson: Advisor/Consultant|Johnson & Johnson: Grant/Research Support|MD: Advisor/Consultant|Moderna: Advisor/Consultant|MSD: Data safety monitoring board|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant|Sanofi Pasteur: Grant/Research Support|Sanofi Pasteur: Data safety monitoring board Liem Binh Luong, MD, Pfizer: Advisor/Consultant|Pfizer: Honoraria Karine Lacombe, MD, PhD, Gilead: Advisor/Consultant|Janssen: Grant/Research Support|MSD: Grant/Research Support|ViiV Healthcare: Grant/Research Support Elisabeth Botelho-Nevers, MD, PHD, Janssen: Board Member|Pfizer: Board Member|Sanofi Pasteur: Board Member.

APA, Harvard, Vancouver, ISO, and other styles

35

LOUBET, Paul, L. I. nda Wittkop, Mathieu Chalouni, David-Axel Laplaud, Martine Laville, Bruno Laviolle, Jean-Daniel Lelièvre, et al. "84. One-month Humoral Response Following Two Doses of Covid-19 Vaccines in Specific populations – ANRS0001S COV POPART Cohort Study." Open Forum Infectious Diseases 9, Supplement_2 (December 1, 2022). http://dx.doi.org/10.1093/ofid/ofac492.009.

Full text

Abstract:

Abstract Background We evaluated the immune response to COVID-19 vaccines in several specific populations at high risk of severe COVID-19. Methods Participants from the French national multi-center prospective cohort study ANRS0001S COV-POPART were included (11 specific subpopulations: and 2 control groups (18–64 years and over 65 years)). In this preliminary analysis patients and controls who had received at least two vaccine doses have been included. Percentages (95% confidence intervals (CI)) of participants with anti-Spike SARS-CoV-2 IgG antibodies (ELISA) and specific neutralizing antibodies (in vitro neutralization assay) were evaluated at one month after the second dose of COVID-19 vaccine. Results 3703 were included: 2650 participants from specific subpopulations (171 solid cancers, 160 SOT, 100 HCT, 91 chronic renal failures, 141 systemic autoimmune diseases, 157 autoimmune inflammatory rheumatic diseases, 361 multiple sclerosis (MS) or neuromyelitis optica spectrum disorders, 61 hypogammaglobulinemia, 401 diabetic, 739 obeses non-diabetic and 476 HIV) and 1053 controls (893: 18–64 years and 160 over 65 years). Median age was 51.7 years [InterQuartile range: 40.8 – 60.9] and 50.7% were male. Most of the participants received BNT162b2 vaccine (86.4%). In the control group, 100% (95%CI: 99.6;100.0) of those aged 18–64 and 99.4% (96.6; 100.0) of those over 65 years developed anti-Spike IgG antibodies. PLWHIV, cancer and diabetic patients had high rate of responders after two doses with 98.3% (97.2;99.1), 93.0% (88.1;96.3) and 92.0% (88.9;94.5), respectively. The lowest percentage of responders was found in patients with SOT (13.8% (8.8;20.1), HSCT (34.0% (24.8;44.2) and hypogammaglobulinemia (52.5% 39.3;65.4). In both control groups, the frequency of neutralizing antibodies was similar to the anti-Spike IgG antibody response. In the immunodeficient populations, neutralizing antibodies responders tended to be less frequent than anti-Spike antibodies responders. Similar trends than for IgG antibody were identified (Figure 1). Anti-Spike and Neutralizing antibody (Ab) responses (95% CI) one month after the second dose of COVID-19 vaccine in specific and control populations. Conclusion Lower COVID-19 vaccine humoral response was observed in specific populations than in controls, especially in patients with hypogammaglobulinemia, HSCT and SOT. Disclosures Paul LOUBET, MD, PhD, pfizer: Board Member Odile Launay, MD, PhD, AstraZeneca: Financial|GlaxoSmithKline: Advisor/Consultant|GlaxoSmithKline: Grant/Research Support|Johnson & Johnson: Advisor/Consultant|Johnson & Johnson: Grant/Research Support|MD: Advisor/Consultant|Moderna: Advisor/Consultant|MSD: Data safety monitoring board|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Sanofi Pasteur: Advisor/Consultant|Sanofi Pasteur: Grant/Research Support|Sanofi Pasteur: Data safety monitoring board.

APA, Harvard, Vancouver, ISO, and other styles

36

"La Langue sous le feu. Mots, textes, discours de la Grande Guerre, Odile Roynette, Gilles Siouffi et Agnès Steuckardt (dir.) , Presses universitaires de Rennes, 2017." Inflexions N° 36, no. 3 (September 1, 2017): XVI. http://dx.doi.org/10.3917/infle.036.0227p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Grand Odile'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles